novo nordisk fda semaglutide Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk just played one

2020, Apr

PK, pharmacokinetics

While BPC-157 may partially counteract some effects through angiogenesis promotion, smoking likely reduces overall results

Start Your Weight Loss Journey Safely and Effectively Reaching a healthy weight is within your reach

Metrics & Citations Metrics Altmetrics Citations Export citation Select the format you want to export the citation of this publication

FDA-approved GLP-1 medications are generally considered safe for most people, but there are quite a few people who should avoid them altogether, including those who have: Family history of thyroid cancer Family history of pancreatitis Gastrointestinal conditions Pregnancy or breastfeeding Diabetic retinopathy History of eating disorders Each of these GLP-1 medications provides important safety information on its website, including possible side effects from taking the drug